Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization

[1]  V. Diehl,et al.  Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM). , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Martino,et al.  HIGH‐DOSE ETOPOSIDE ENABLES THE COLLECTION OF PERIPHERAL BLOOD STEM CELLS IN PATIENTS WHO FAILED CYCLOPHOSPHAMIDE‐INDUCED MOBILIZATION , 1998, British journal of haematology.

[3]  A. Zelenetz,et al.  Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  A. Pileri,et al.  Peripheral blood progenitor cell mobilization in patients with primary refractory lymphoma or at first relapse: comparison with patients at diagnosis and impact on clinical outcome , 1997, British journal of haematology.

[5]  N. Russell,et al.  Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate‐dose cyclophosphamide , 1997, British journal of haematology.

[6]  R. Storb,et al.  Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Linch,et al.  Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Copelan,et al.  Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Goldschmidt,et al.  Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. , 1996, Bone marrow transplantation.

[10]  N. Kröger,et al.  Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis. , 1996, Bone marrow transplantation.

[11]  N. Schmitz,et al.  Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients , 1996, The Lancet.

[12]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[13]  N. Schmitz,et al.  Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. , 1995, Blood.

[14]  A. Pileri,et al.  Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short intervals between drug courses severely impair progenitor mobilization. , 1995, Bone marrow transplantation.

[15]  J. Nemunaitis,et al.  Cyclophosphamide-mobilized peripheral blood stem cells in patient with lymphoid malignancies. , 1995, Bone marrow transplantation.

[16]  渡邉 茂樹.  Peripheral blood stem cell mobilization with chemotherapy and granulocyte-colony stimulating factor in patients with hematological malignancies , 1995 .

[17]  H. Goldschmidt,et al.  Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. , 1994, Blood.

[18]  A. Santoro,et al.  High dose cyclophosphamide: stem cell mobilizing capacity in 21 patients. , 1994, Leukemia & lymphoma.

[19]  N. Schmitz,et al.  Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Goldstone,et al.  Comparison of peripheral blood stem-cell and autologous bone marrow transplantation for lymphoma patients: a case-controlled analysis of the EBMT Registry data. Lymphoma Working Party of the EBMT. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  D. Crowther,et al.  Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. , 1993, Blood.

[22]  A. Santoro,et al.  Cyclophosphamide 4 g/m2 Plus rhG-CSF for Mobilization of Circulating Progenitor Cells in Malignant Lymphomas , 1993, The International journal of artificial organs.

[23]  A. Tedeschi,et al.  PBSC Collection after High Dose Chemotherapy Followed by G-CSF in Patients with Malignancies: Analysis of Results regarding Factors Affecting the Yield of Hemopoietic Progenitors , 1993, The International journal of artificial organs.

[24]  D. Winfield,et al.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.

[25]  A. Pileri,et al.  Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  W. Vainchenker,et al.  Hematopoietic growth factors and human megakaryocyte differentiation. , 1992, Bone marrow transplantation.

[27]  A. Bolton,et al.  Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. , 1992, Bone marrow transplantation.

[28]  L. To,et al.  Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry. , 1991, Blood.

[29]  C. Civin,et al.  Single cell origin of multilineage colonies in culture. Evidence that differentiation of multipotent progenitors and restriction of proliferative potential of monopotent progenitors are stochastic processes. , 1984, The Journal of clinical investigation.